PRME - NASDAQ
Prime Medicine, Inc.
$3.21
-2.2%Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotPrime Medicine, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Prime Medicine, Inc. Income Statement
PRME • NASDAQ
| Prime Medicine, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
4.6M | 3M | 0.0 | 0.0 | 0.0 | 5.2M | 0.0 | |
GROSS PROFIT | |||||||
(7.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (3M) | (2.8M) | |
-2.7M | 3M | 0.0 | 0.0 | 0.0 | 2.2M | -2.8M | |
OPERATING INCOME | |||||||
(205.7M) | (205.5M) | (204.8M) | (116.5M) | (84.5M) | (3.2M) | (2.2M) | |
(52.3M) | (50.2M) | (43.4M) | (29.8M) | (13.9M) | (3.2M) | (1.3M) | |
(160.6M) | (155.3M) | (147.9M) | (86.7M) | (70.6M) | (3M) | (920K) | |
-208.4M | -202.5M | -204.8M | -116.5M | -84.5M | -932K | -2.2M | |
PRE-TAX INCOME | |||||||
4.1M | 3.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-7.3M | (0.0) | (13.5M) | (0.0) | (0.0) | -3M | (0.0) | |
7.2M | 6.6M | 6.4M | -6.2M | -81.4M | -611K | 0.0 | |
-201.1M | -195.9M | -198.4M | -122.8M | -165.9M | -1.5M | -2.5M | |
NET INCOME | |||||||
(0.0) | (0.0) | -279K | -948K | -486K | (1.9M) | (4K) | |
-201.1M | -195.9M | -198.1M | -121.8M | -165.4M | -3.4M | -2.5M |
SEC Filings
PRME - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 07, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 07, 2025 | November 07, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 07, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 08, 2025 | September 08, 2025 | 2025 |
Related Guides
Continue your PRME research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.